Theophylline
- Generic Name
- Theophylline
- Brand Names
- Elixophyllin, Elixophylline, Pulmophylline, Quibron-T, Theo-24, Theolair, Uniphyl
- Drug Type
- Small Molecule
- Chemical Formula
- C7H8N4O2
- CAS Number
- 58-55-9
- Unique Ingredient Identifier
- 0I55128JYK
- Background
A methylxanthine derivative from tea with diuretic, smooth muscle relaxant, bronchial dilation, cardiac and central nervous system stimulant activities. Mechanistically, theophylline acts as a phosphodiesterase inhibitor, adenosine receptor blocker, and histone deacetylase activator. Theophylline is marketed under several brand names such as Uniphyl and Theochron, and it is indicated mainly for asthma, bronchospasm, and COPD.
- Indication
For the treatment of the symptoms and reversible airflow obstruction associated with chronic asthma and other chronic lung diseases, such as emphysema and chronic bronchitis.
- Associated Conditions
- Asthma, Bronchitis, Bronchoconstriction, Bronchospasm, Chronic Obstructive Pulmonary Disease (COPD), Chronic bronchial inflammation
- Associated Therapies
- Airway secretion clearance therapy, Bronchodilation
Association Between CytochromeP4501A2 and CytochromeP4502E1 Gene Polymorphisms and Metabolism of Theophylline
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- First Posted Date
- 2013-12-05
- Last Posted Date
- 2014-08-20
- Lead Sponsor
- Zhujiang Hospital
- Target Recruit Count
- 102
- Registration Number
- NCT02001935
- Locations
- 🇨🇳
Zhujiang Hospital,Southern Medical Universtiy, Guangzhou, Guangdong, China
Combination of gp96-Ig Vaccine, Theophylline and Oxygen for the Treatment of Patients With Advanced, Relapsed or Metastatic Non-Small Cell Lung Cancer
- Conditions
- Non-small-cell Lung CarcinomaLung CancerNSCLCNon-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2013-02-26
- Last Posted Date
- 2014-11-17
- Lead Sponsor
- Eckhard Podack
- Registration Number
- NCT01799161
The Role of Theophylline Plus Low-dose Formoterol-budesonide in Treatment of Bronchiectasis
- Conditions
- Bronchiectasis
- Interventions
- First Posted Date
- 2013-01-17
- Last Posted Date
- 2015-03-11
- Lead Sponsor
- The First Affiliated Hospital of Guangzhou Medical University
- Target Recruit Count
- 50
- Registration Number
- NCT01769898
- Locations
- 🇨🇳
State Key Laboratory of Respiratory Research Institute., Guangzhou City, Guangdong, China
🇨🇳The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China
The Effect of Theophylline in the Treatment of Bronchiectasis
- Conditions
- Bronchiectasis
- Interventions
- Drug: Placebo(for Theophylline)Drug: Theophylline
- First Posted Date
- 2012-09-13
- Last Posted Date
- 2015-03-11
- Lead Sponsor
- The First Affiliated Hospital of Guangzhou Medical University
- Target Recruit Count
- 100
- Registration Number
- NCT01684683
- Locations
- 🇨🇳
State Key Laboratory of Respiratory Research Institute., Guangzhou City, Guangdong, China
Drug Interaction Study of Colchicine and Theophylline
- First Posted Date
- 2012-05-17
- Last Posted Date
- 2013-06-17
- Lead Sponsor
- Takeda
- Target Recruit Count
- 30
- Registration Number
- NCT01601132
- Locations
- 🇺🇸
Worlwide Clinical Trials Drug Development Solutions, Clinical Research Services, San Antonio, Texas, United States
Low-dose Theophylline as Anti-inflammatory Enhancer in Severe Chronic Obstructive Pulmonary Disease
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Other: placeboDrug: theophylline
- First Posted Date
- 2012-05-16
- Last Posted Date
- 2017-08-29
- Lead Sponsor
- Hospital Son Espases
- Target Recruit Count
- 70
- Registration Number
- NCT01599871
- Locations
- 🇪🇸
Clínica Universitaria de Navarra, Pamplona, Navarra, Spain
🇪🇸Hospital del Mar, Barcelona, Spain
🇪🇸Hospital Clínic de Barcelona, Barcelona, Spain
A Study of LY2216684 and Theophylline in Healthy Subjects
- First Posted Date
- 2010-12-20
- Last Posted Date
- 2019-07-08
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 21
- Registration Number
- NCT01263106
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dallas, Texas, United States
CO2 Inhalation as a New Treatment Modality for Apnea of Prematurity
- First Posted Date
- 2010-02-10
- Last Posted Date
- 2010-03-03
- Lead Sponsor
- University of Manitoba
- Target Recruit Count
- 87
- Registration Number
- NCT01066728
- Locations
- 🇨🇦
Health Sciences Centre, Winnipeg, Manitoba, Canada
🇨🇦St Boniface General Hospital, Winnipeg, Manitoba, Canada
A Drug-Drug Interaction Study of Abiraterone Acetate Plus Prednisone With Dextromethorphan and Theophylline in Patients With Metastatic Castration-Resistant Prostate Cancer
- Conditions
- Prostate Neoplasms
- Interventions
- First Posted Date
- 2009-11-23
- Last Posted Date
- 2013-04-12
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 34
- Registration Number
- NCT01017939
- Locations
- 🇺🇸
START - South Texas Accelerated Research Therapeutics, LLC, San Antonio, Texas, United States
🇺🇸Tower Cancer Research Foundation, Beverly Hills, California, United States
🇨🇦BC Cancer Agency, Vancouver, British Columbia, Canada
Drug-Drug Interaction Study of Colchicine and Theophylline
- First Posted Date
- 2009-09-24
- Last Posted Date
- 2010-03-02
- Lead Sponsor
- Mutual Pharmaceutical Company, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT00983905
- Locations
- 🇺🇸
PRACS Institute, Ltd. - Cetero Research, Fargo, North Dakota, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.